What’s Old Is New Again: Bristol Cancer Plans Re-Emphasize Cytotoxics

Bristol-Myers Squibb is aiming to recapture its leadership in oncology by focusing on developing novel cytotoxic agents as well as concentrating on the emerging field of targeted therapies, Chief Scientific Officer Elliott Sigal said during a post-ASCO call